Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens

被引:13
作者
Crandon, Jared [1 ]
Nicolau, David P. [1 ,2 ]
机构
[1] Hartford Hosp, Ctr Anti Infect Res & Dev, Ishikari, Hokkaido 06102, Japan
[2] Hartford Hosp, Div Infect Dis, Hartford, CT 06115 USA
关键词
glycopeptide; LY333328; oritavancin; Staphylococcus aureus; vancomycin-resistant Enterococcus;
D O I
10.2217/17460913.3.3.251
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Oritavancin is a lipoglycopeptide antibiotic with activity against aerobic and anaerobic Gram-positive bacteria. Oritavancin separates itself from other glycopeptides through its potent in vitro activity against resistant isolates of Staphylococcus aureus, Enterococcus spp. and Streptococcus spp. Oritavancin possesses a long half-life that should allow, at maximum, once-daily dosing. Currently, oritavancin has completed two Phase III trials and one Phase II trial for the treatment of complicated skin and skin structure infections, and two Phase II trials for the treatment of Gram-positive bacteremia. In all instances, oritavancin displayed favorable outcomes and was noninferior to comparator agents (vancomycin followed by oral cephalexin) when a comparison was made. Further studies are necessary to fully characterize dose and clinical role.
引用
收藏
页码:251 / 263
页数:13
相关论文
共 60 条
[51]   Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis [J].
Saleh-Mghir, A ;
Lefort, A ;
Petegnief, Y ;
Dautrey, S ;
Vallois, JM ;
Le Guludec, D ;
Carbon, C ;
Fantin, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (01) :115-120
[52]  
SERAL C, 2002, 42 INT C ANT AG CHEM
[53]   The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America [J].
Spellberg, Brad ;
Guidos, Robert ;
Gilbert, David ;
Bradley, John ;
Boucher, Helen W. ;
Scheld, W. Michael ;
Bartlett, John G. ;
Edwards, John, Jr. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (02) :155-164
[54]   Enterococcus faecium bacteremia -: Does vancomycin resistance make difference? [J].
Stosor, V ;
Peterson, LR ;
Postelnick, M ;
Noskin, GA .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (05) :522-527
[55]   Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation [J].
Van Bambeke, F ;
Saffran, J ;
Mingeot-Leclercq, MP ;
Tulkens, PM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (05) :1695-1700
[56]  
VANBAMBEKE F, 2001, 11 EUR C CLIN MICR I
[57]  
VANBAMBEKE F, 2001, 41 INT C ANT AG CHEM
[58]  
WANG TSA, 2007, 47 INT C ANT AG CHEM
[59]  
WASILEWSKI M, 2001, 41 INT C ANT AG CHEM
[60]   Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains [J].
Zelenitsky, SA ;
Karlowsky, JA ;
Zhanel, GG ;
Hoban, DJ ;
Nicas, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1407-1408